Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
US Department of Justice
McKinsey
Healthtrust
Moodys
Teva
Accenture
Dow
AstraZeneca
Cantor Fitzgerald

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,635,704

« Back to Dashboard

Summary for Patent: 7,635,704
Title:Stable crystal of 4-oxoquinoline compound
Abstract: Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2.theta.(.degree.) as measured by X-ray powder diffractmetry.
Inventor(s): Satoh; Motohide (Osaka, JP), Motomura; Takahisa (Osaka, JP), Matsuda; Takashi (Osaka, JP), Kondo; Kentaro (Osaka, JP), Ando; Koji (Osaka, JP), Matsuda; Koji (Osaka, JP), Miyake; Shuji (Osaka, JP), Uehara; Hideto (Osaka, JP)
Assignee: Japan Tobacco Inc. (Tokyo, JP)
Application Number:11/133,471
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 7,635,704

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc GENVOYA cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 207561-001 Nov 5, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HIV INFECTION ➤ Sign Up
Gilead Sciences Inc STRIBILD cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 203100-001 Aug 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HIV INFECTION ➤ Sign Up
Gilead Sciences Inc VITEKTA elvitegravir TABLET;ORAL 203093-001 Sep 24, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HIV INFECTION ➤ Sign Up
Gilead Sciences Inc VITEKTA elvitegravir TABLET;ORAL 203093-002 Sep 24, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HIV INFECTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,635,704

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-150979May 20, 2004

Non-Orange Book US Patents Family Members for Patent 7,635,704

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,981,103 Stable crystal of 4-oxoquinoline compound ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,635,704

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2566922 ➤ Sign Up
China 1956961 ➤ Sign Up
Cyprus 1113010 ➤ Sign Up
Denmark 1636190 ➤ Sign Up
European Patent Office 1636190 ➤ Sign Up
European Patent Office 2514746 ➤ Sign Up
Spain 2388441 ➤ Sign Up
Hong Kong 1083341 ➤ Sign Up
Croatia P20120681 ➤ Sign Up
Israel 179250 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Deloitte
Queensland Health
Colorcon
Cipla
Fish and Richardson
Express Scripts
Cerilliant
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot